Covance offers a broad range of contract drug development services globally from preclinical through post-approval stages, including monitoring and managing clinical trials, and advising clients on global regulatory applications.
The Chinese central laboratory was set up in Shanghai inAugust, 2007. The investment reached more than RM 40 million with the floor area of 1212 sq. m. and it can provide over 100 tests.
In collaboration with the China Innovation Center for Life Sciences (CICLS), an office of the Chinese Ministry of Science and Technology (MOST), and leading Chinese pharmaceutical companies, Covance will be the first company in its field to test traditional Chinese medicines for approval by the U.S. Food and Drug Administration (FDA).
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.3 billion, global operations in more than 20 countries, and more than 8,400 employees worldwide. Offering drug development solutions from preclinical through commercialization, Covance is a world-class provider of the following service lines: Research products, Antibody products and services, Nonclinical development services, Risk management services, Clinical pharmacology services, Central laboratory/Covance local laboratory services, Cardiac safety services, Clinical development services, Commercialization services.